CG Oncology CGON Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's accrued expenses and other liabilities?
- CG Oncology (CGON) reported accrued expenses and other liabilities of $25.91M in Q1 2026.
- How has CG Oncology's accrued expenses and other liabilities changed year-over-year?
- CG Oncology's accrued expenses and other liabilities increased by 65.5% year-over-year, from $15.66M to $25.91M.
- What is the long-term trend for CG Oncology's accrued expenses and other liabilities?
- Over 2 years (2023 to 2025), CG Oncology's accrued expenses and other liabilities has grown at a 52.3% compound annual growth rate (CAGR), from $10.44M to $24.21M.